The move to make pharma more transparent and build a positive reputation is the key theme to come out of the launch of the new ABPI Code of Practice during Code Awareness Week. The move to make pharma ...

More detailed requirements for pharmaceutical companies’ relationships with patient groups and health professionals will be included in the revised ABPI Code of Practice which comes into effect on ...

Novo Nordisk’s two-year suspension from the Association of the British Pharmaceutical Industry (ABPI) for serious breaches of the ABPI Code of Practice has come to an end [1]. Novo Nordisk’s return to ...

Life sciences digital agency Genetic Digital has launched Pi 360, a cutting-edge web application designed to help pharmaceutical companies automate the creation, management and distribution of ...

After Novo Nordisk breached not one, not two, but seven clauses of the code that regulates U.K. drugmakers, its U.K. general manager is stepping down as president of the industry's national ...

Angelini was ruled in breach of Clause 2 of the 2021 Code in relation to an in-person presentation by a contracted speaker at a company-organised promotional meeting, and its recording, which ...

Investing.com -- After a two-year suspension due to serious breaches of the Association of the British Pharmaceutical (TADAWUL:2070) Industry (ABPI) Code of Practice, Novo Nordisk (NYSE:NVO) has been ...

The pharmaceutical company had previously been subjected to a 2-year suspension. The Association of the British Pharmaceutical Industry (ABPI) reinstated Novo Nordisk’s membership in the group. 1 The ...

LONDON, March 16 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab has been suspended from the Association of the British Pharmaceutical Industry (ABPI) for two years over what the ...

LONDON (Reuters) -Danish drugmaker Novo Nordisk has been suspended from the Association of the British Pharmaceutical Industry (ABPI) for two years over what the ABPI on Thursday described as "serious ...

UK pharmaceutical companies have historically relied upon consent as the lawful basis for the disclosure of healthcare professionals’ personal data relating to transfers of value. However, the low ...